Reproducibility of the In Vivo Effect of the Selective Serotonin Reuptake Inhibitors on the In Vivo Function of Cytochrome P450 2D6: An Update (Part I)

SHELDON H. PRESKORN, MD, is Professor and Chairman, Department of Psychiatry, University of Kansas School of Medicine-Wichita, and Medical Director, Psychiatric Research Institute, Wichita, Kansas. He has more than 25 years of drug development research experience at all levels (i.e., preclinical through Phase IV) and has been a principal investigator on over 150 clinical trials including every antidepressant marketed in the United States over the last 15 years. Dr. Preskorn maintains a website at <http://www.preskorn.com> where readers can access previous columns and other publications.